Targeted Cytotoxic Therapy Kills Persisting HIV Infected Cells During ART

PLoS Pathogens

Volumn 10, Issue 1, 2014, Pages

  Denton, Paul W ^a   Long, Julie M ^a   Wietgrefe, Stephen W ^b   Sykes, Craig ^c   Spagnuolo, Rae Ann ^a   Snyder, Olivia D ^a   Perkey, Katherine ^b   Archin, Nancie M ^a   Choudhary, Shailesh K ^a   Yang, Kuo ^c   Hudgens, Michael G ^d   Pastan, Ira ^e   Haase, Ashley T ^b   Kashuba, Angela D ^c   Berger, Edward A ^f   Margolis, David M ^a   Garcia, J Victor ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNC Hamner Institute for Drug Safety Sciences   (United States)

^d University of North Carolina at Chapel Hill   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; IMMUNOTOXIN; VIRUS RNA;

ANIMAL; BLOOD; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; SCID MOUSE;

ANIMALS; ANTI-RETROVIRAL AGENTS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTOXINS; MICE; MICE, INBRED NOD; MICE, SCID; RNA, VIRAL;

EID: 84893815335     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003872     Document Type: Article

References (59)

1. Nakagawa F, May M, Phillips A, (2013) Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis 26: 17-25.
2. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, et al. (2009) The challenge of finding a cure for HIV infection. Science 323: 1304-1307.
3. Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, et al. (2012) Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 12: 607-614.
4. Durand CM, Blankson JN, Siliciano RF, (2012) Developing strategies for HIV-1 eradication. Trends Immunol 33: 554-562.
5. Deeks SG, (2012) HIV: Shock and kill. Nature 487: 439-440.
6. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, et al. (2012) Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36: 491-501.
7. Hamer DH, (2004) Can HIV be Cured? Mechanisms of HIV persistence and strategies to combat it. Curr HIV Res 2: 99-111.
8. Berger EA, Pastan I, (2010) Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs. PLoS Pathog 6: e1000803.
9. Thrush GR, Lark LR, Clinchy BC, Vitetta ES, (1996) Immunotoxins: an update. Annu Rev Immunol 14: 49-71.
10. Pincus SH, (1996) Therapeutic potential of anti-HIV immunotoxins. Antiviral Res 33: 1-9.
11. Van Oijen MG, Preijers FW, (1998) Rationale for the use of immunotoxins in the treatment of HIV-infected humans. J Drug Target 5: 75-91.
12. Liu S, Schubert RL, Bugge TH, Leppla SH, (2003) Anthrax toxin: structures, functions and tumour targeting. Expert Opin Biol Ther 3: 843-853.
13. Engert A, Sausville EA, Vitetta E, (1998) The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma. Curr Top Microbiol Immunol 234: 13-33.
14. Till MA, Zolla-Pazner S, Gorny MK, Patton JS, Uhr JW, et al. (1989) Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain. Proc Natl Acad Sci U S A 86: 1987-1991.
15. Pincus SH, Wehrly K, Chesebro B, (1989) Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates. J Immunol 142: 3070-3075.
16. Till MA, Ghetie V, Gregory T, Patzer EJ, Porter JP, et al. (1988) HIV-infected cells are killed by rCD4-ricin A chain. Science 242: 1166-1168.
17. Chaudhary VK, Mizukami T, Fuerst TR, FitzGerald DJ, Moss B, et al. (1988) Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein. Nature 335: 369-372.
18. Berger EA, Clouse KA, Chaudhary VK, Chakrabarti S, FitzGerald DJ, et al. (1989) CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses. Proc Natl Acad Sci U S A 86: 9539-9543.
19. Bell KD, Ramilo O, Vitetta ES, (1993) Combined use of an immunotoxin and cyclosporine to prevent both activated and quiescent peripheral blood T cells from producing type 1 human immunodeficiency virus. Proc Natl Acad Sci U S A 90: 1411-1415.
20. McCoig C, Van Dyke G, Chou CS, Picker LJ, Ramilo O, et al. (1999) An anti-CD45RO immunotoxin eliminates T cells latently infected with HIV-1 in vitro. Proc Natl Acad Sci U S A 96: 11482-11485.
21. Pincus SH, McClure J, (1993) Soluble CD4 enhances the efficacy of immunotoxins directed against gp41 of the human immunodeficiency virus. Proc Natl Acad Sci U S A 90: 332-336.
22. Bera TK, Kennedy PE, Berger EA, Barbas CF 3rd, Pastan I, (1998) Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein. Mol Med 4: 384-391.
23. Cory TJ, Schacker TW, Stevenson M, Fletcher CV, (2013) Overcoming pharmacologic sanctuaries. Curr Opin HIV AIDS 8: 190-195.
24. Melkus MW, Estes JD, Padgett-Thomas A, Gatlin J, Denton PW, et al. (2006) Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med 12: 1316-1322.
25. Denton PW, Garcia JV, (2011) Humanized mouse models of HIV infection. AIDS Rev 13: 135-148.
26. Denton PW, Garcia JV, (2012) Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice. Trends Microbiol 20: 268-274.
27. Denton PW, Nochi T, Lim A, Krisko JF, Martinez-Torres F, et al. (2012) IL-2 receptor gamma-chain molecule is critical for intestinal T-cell reconstitution in humanized mice. Mucosal Immunol 5: 555-566.
28. Long BR, Stoddart CA, (2012) Alpha interferon and HIV infection cause activation of human T cells in NSG-BLT mice. J Virol 86: 3327-3336.
29. Brainard DM, Seung E, Frahm N, Cariappa A, Bailey CC, et al. (2009) Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol 83: 7305-7321.
30. Zou W, Denton PW, Watkins RL, Krisko JF, Nochi T, et al. (2012) Nef functions in BLT mice to enhance HIV-1 replication and deplete CD4+CD8+ thymocytes. Retrovirology 9: 44.
31. Sun Z, Denton PW, Estes JD, Othieno FA, Wei BL, et al. (2007) Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J Exp Med 204: 705-714.
32. Denton PW, Estes JD, Sun Z, Othieno FA, Wei BL, et al. (2008) Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 5: e16.
33. Jilek BL, Zarr M, Sampah ME, Rabi SA, Bullen CK, et al. (2012) A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat Med 18: 446-451.
34. Rockstroh JK, Dejesus E, Lennox JL, Yazdanpanah Y, Saag MS, et al. (2013) Durable Efficacy and Safety of Raltegravir versus Efavirenz When Combined With Tenofovir/Emtricitabine In Treatment-Naive HIV-1 Infected Patients: Final Five-Year Results From STARTMRK. J Acquir Immune Defic Syndr 63 (1) (): 77-85.
35. Denton PW, Olesen R, Choudhary SK, Archin NM, Wahl A, et al. (2012) Generation of HIV latency in BLT humanized mice. J Virol 86: 630-634.
36. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, et al. (2008) Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 105: 3879-3884.
37. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, et al. (1997) Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277: 112-116.
38. Murray JM, McBride K, Boesecke C, Bailey M, Amin J, et al. (2012) Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards. AIDS 26: 543-550.
39. Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A, (1998) Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother 42: 612-617.
40. Schinazi RF, McMillan A, Cannon D, Mathis R, Lloyd RM, et al. (1992) Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother 36: 2423-2431.
41. Scopelliti F, Pollicita M, Ceccherini-Silberstein F, Di Santo F, Surdo M, et al. (2011) Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes. Antiviral Res 92: 255-261.
42. Lafeuillade A, Khiri H, Chadapaud S, Hittinger G, Halfon P, (2001) Persistence of HIV-1 resistance in lymph node mononuclear cell RNA despite effective HAART. AIDS 15: 1965-1969.
43. Kennedy PE, Bera TK, Wang QC, Gallo M, Wagner W, et al. (2006) Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques. J Leukoc Biol 80: 1175-1182.
44. Goldstein H, Pettoello-Mantovani M, Bera TK, Pastan IH, Berger EA, (2000) Chimeric toxins targeted to the human immunodeficiency virus type 1 envelope glycoprotein augment the in vivo activity of combination antiretroviral therapy in thy/liv-SCID-Hu mice. J Infect Dis 181: 921-926.
45. Blankson JN, Finzi D, Pierson TC, Sabundayo BP, Chadwick K, et al. (2000) Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection. J Infect Dis 182: 1636-1642.
46. Sedaghat AR, Dinoso JB, Shen L, Wilke CO, Siliciano RF, (2008) Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci U S A 105: 4832-4837.
47. Horwitz JA, Halper-Stromberg A, Mouquet H, Gitlin AD, Tretiakova A, et al. (2013) HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci U S A 110: 16538-16543.
48. Barbas CF 3rd, Hu D, Dunlop N, Sawyer L, Cababa D, et al. (1994) In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc Natl Acad Sci U S A 91: 3809-3813.
49. North TW, Higgins J, Deere JD, Hayes TL, Villalobos A, et al. (2010) Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol 84: 2913-2922.
50. Yukl SA, Shergill AK, Ho T, Killian M, Girling V, et al. (2013) The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence. J Infect Dis 208: 1212-1220.
51. Woo JH, Frankel A, Neville DM, (2010) Cytotoxic therapy with diphtheria toxin fusion proteins. Drugs of the Future 35: 823-831.
52. Weldon JE, Pastan I, (2011) A guide to taming a toxin-recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J 278: 4683-4700.
53. Fang H, Pincus SH, (1995) Unique insertion sequence and pattern of CD4 expression in variants selected with immunotoxins from human immunodeficiency virus type 1-infected T cells. J Virol 69: 75-81.
54. Berger EA, (2011) Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs. Curr Opin HIV AIDS 6: 80-85.
55. Mitsuyasu R, (2013) Curing HIV: lessons from cancer therapy. Curr Opin HIV AIDS 8: 224-229.
56. Denton PW, Othieno F, Martinez-Torres F, Zou W, Krisko JF, et al. (2011) One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J Virol 85: 7582-7593.
57. Wahl A, Swanson MD, Nochi T, Olesen R, Denton PW, et al. (2012) Human breast milk and antiretrovirals dramatically reduce oral HIV-1 transmission in BLT humanized mice. PLoS Pathog 8: e1002732.
58. Krisko JF, Martinez-Torres F, Foster JL, Garcia JV, (2013) HIV Restriction by APOBEC3 in Humanized Mice. PLoS Pathog 9: e1003242.
59. Haase AT, Henry K, Zupancic M, Sedgewick G, Faust RA, et al. (1996) Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 274: 985-989.